The GOG Foundation Inc.(@GOG) 's Twitter Profile Photo

The Evolving Landscape in Molecular-Driven Investigational Therapies for Advanced Endometrial Cancer Enduring Education Materials are now available on the GOG Past Events web page! Click link in bio or go to ow.ly/PtYO50Rwl3J.

account_circle
OBSTETRICS & GYNECOLOGY CONNECT(@OBGynConnect) 's Twitter Profile Photo

⚡MITO END-3: Of 125 patients, 29 were MSI-H with high TMB. Avelumab's effect on survival varied: favourable in MSI-H and worse in MSS/TP53 mut. ARID1A and PTEN mutations showed significant treatment interaction.



ow.ly/3OA550Rxh21

⚡MITO END-3: Of 125 patients, 29 were MSI-H with high TMB. Avelumab's effect on survival varied: favourable in MSI-H and worse in MSS/TP53 mut. ARID1A and PTEN mutations showed significant treatment interaction. 

#MedEd #EndometrialCancer

ow.ly/3OA550Rxh21
account_circle
GSK Australia(@GSK_AU) 's Twitter Profile Photo

Jemperli, our immunotherapy, is now funded under the Pharmaceutical Benefit Scheme for Australian women with first line advanced or recurrent dMMR . This is the first subsidised treatment in decades in the first line for this type of cancer.

Find out more:…

Jemperli, our immunotherapy, is now funded under the Pharmaceutical Benefit Scheme for Australian women with first line advanced or recurrent dMMR #EndometrialCancer. This is the first subsidised treatment in decades in the first line for this type of cancer.

Find out more:…
account_circle
A S Lifeline Cancer Care Hospital(@aslifelinecare) 's Twitter Profile Photo

Did you know? Hormonal therapy isn't just for breast and prostate cancers. It can also benefit other hormone-sensitive cancers like ovarian and endometrial. Learn more at aslifelinecancercare.com
.
.

Did you know? Hormonal therapy isn't just for breast and prostate cancers. It can also benefit other hormone-sensitive cancers like ovarian and endometrial. Learn more at aslifelinecancercare.com
.
.
#CancerAwareness #HormonalTherapy #OvarianCancer #EndometrialCancer #Healthcare
account_circle
Ross Harrison, MD MPH(@RossFH) 's Twitter Profile Photo

Adding cisplatin to radiation doesn't improve progression-free survival for localized recurrent but does increase treatment-related toxicity. Radiation remains standard of care. ascopubs.org/doi/10.1200/JC… Journal of Clinical Oncology Ann Klopp David Scott Miller

Adding cisplatin to radiation doesn't improve progression-free survival for localized recurrent #endometrialcancer but does increase treatment-related toxicity. Radiation remains standard of care. ascopubs.org/doi/10.1200/JC… @JCO_ASCO @AnnKloppMD @dsmgyo #gyncsm #gynonc
account_circle
Journal of Molecular Pathology MDPI(@JMP_MDPI) 's Twitter Profile Photo

At the start of May, we invite you to read the latest publication from the Journal of Molecular : 'Molecular Profiling of H-MSI/dMMR/for Patients: “New Challenges in Diagnostic Routine Practice”', by Giancarlo Troncone, etc: mdpi.com/2764284☀️

At the start of May, we invite you to read the latest publication from the Journal of Molecular #Pathology: 'Molecular Profiling of H-MSI/dMMR/for #EndometrialCancer Patients: “New Challenges in Diagnostic Routine Practice”', by Giancarlo Troncone,  etc: mdpi.com/2764284☀️
account_circle
The Innovation Oncology(@InnovOncology) 's Twitter Profile Photo

Prognostic impact and causality of on oncological in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials

The Lancet Oncology OncoDaily OncoAlert

thelancet.com/journals/lanon…

Prognostic impact and causality of #age on oncological #outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials

@TheLancetOncol #Oncology #endometrialcancer @oncodaily @OncoAlert #Meded 

thelancet.com/journals/lanon…
account_circle
ACS Journal Cancer(@JournalCancer) 's Twitter Profile Photo

Read our May 15 issue! 📗

acsjournals.onlinelibrary.wiley.com/toc/10970142/2…

In this issue:
✅ Providing context for the HIPECT4 results by Richard Hoehn et al
Ying Liu et al on MMR-D/MSI-H
✅ Impaired fasting glucose and by Byeong Yun Ahn MD et al

OncoAlert

account_circle
PeerView(@PeerView) 's Twitter Profile Photo

Get expert insight on the latest efficacy & safety data for approved & emerging tx for pts with or in a video featuring Drs. Kathleen Moore, Floor Backes & Bhavana Pothuri. Produced with National Ovarian Cancer Coalition & FdtnForWomensCancer: bit.ly/48S24kQ

account_circle
PeerView(@PeerView) 's Twitter Profile Photo

Get expert insight on the latest efficacy & safety data for approved & emerging tx for pts with or in a video featuring Drs. Kathleen Moore, Floor Backes & Bhavana Pothuri. Produced with National Ovarian Cancer Coalition & FdtnForWomensCancer: bit.ly/48S24kQ

account_circle
Dr. Iván R. González(@Dr_Ivanoncologo) 's Twitter Profile Photo

Interesting results 😱🙌🏻of the MITO END-3 clinical trial highlight that immunotherapy with adjuvant Avelumab and chemotherapy significantly improves survival in patients with advanced .
🌟Response variability associated with molecular profiling was observed:…

Interesting results 😱🙌🏻of the MITO END-3 clinical trial highlight that immunotherapy with adjuvant Avelumab and chemotherapy significantly improves survival in patients with advanced #endometrialcancer. 
🌟Response variability associated with molecular profiling was observed:…
account_circle